Staccato Apomorphine Multi-dose PK and PD in Patients With Parkinson's Disease

Summary

This study will be conducted in subjects with established Parkinson's disease in 2 parts. Part A will examine the tolerability, safety, and pharmacokinetics of AZ-009 dose escalation ; and Part B will assess the tolerability, safety, pharmacokinetics, and pharmacodynamics of AZ-009 compared with placebo in a crossover design

Timeline

Start

2019-10-16

Primary completion

2020-02-28

Completion

2020-03-06

Drugs

Indications